Cassava: What federal investigation?
To view this email as a web page, click here

Today's Rundown

Featured Story

Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

A “very important” part of Merck’s HIV strategy has come off the rails. Just months after talking up the importance of MK-8507, Merck has paused development of the asset in response to midphase data that also raised questions about the backbone of all the company’s planned HIV regimens.

read more

Top Stories

BMS heart drug, center of its $13B MyoKardia buyout, hit by FDA delay

Just days ago, Bristol Myers was touting new data for the targeted heart drug mavacamten. Now, the Big Pharma has announced that the FDA has extended the decision date for the drug, which was nabbed through the $13 billion buyout of MyoKardia.

read more

Cassava ploughs on with 2nd phase 3 trial of Alzheimer's med despite federal investigation

Cassava Sciences is forging ahead with a second phase 3 trial of its troubled Alzheimer's drug just three days after revealing a federal investigation into the company.

read more

Sponsored: Tips on building a resilient cGMP chemical supply chain

Plan for growth and meeting patient demand with cGMP supply chain expert tips on sourcing, mitigating risks, and partner selection from Thermo Fisher Scientific Production Chemicals and Services.

read more

Enanta dumps oral hep B program after safety warnings in early test

Enanta Pharmaceuticals is shutting down work on its oral hepatitis B program for EDP-721 after serious safety red flags were raised in a phase 1 study.

read more

Sponsored: Considerations for Laboratory-Related Operational and Patient Burden in Decentralized Clinical Trials. Clinical Lab Testing in Your Home: Fact or Fiction?

Clinical lab testing at home - fact or fiction? Many operational and patient-related considerations must be taken when using a decentralized approach to specimen collection at or near the trial participant's home.

read more

J&J previews $60B-a-year future with plans to go after viruses that have long evaded vaccine makers

Johnson & Johnson has a lofty goal to become a $60 billion-a-year drugmaker by 2025. To reach that goal, the healthcare giant is going to take a crack at a couple of viruses that have long eluded vaccine makers.

read more

Fresh from $2.5B pact, BridgeBio, Helsinn expand collaboration to cover preclinical cancer prospects

BridgeBio Pharma and Helsinn are tightening their ties. Having teamed up to develop one drug in March, the partners have decided to work together on more prospects, starting with a potentially first-in-class cancer candidate.

read more

Biogen's Aduhelm 'likely' linked to Alzheimer's patient's death, RBC analyst says

In the aftermath of an Alzheimer's patient's death, Biogen and industry watchers have been trying to piece together the situation and determine whether the company's recently minted Alzheimer's drug should carry any blame. The answer? Probably so, one analyst says.

read more

Labcorp adds to drug development, device testing services with Toxikon buy

Situating the Massachusetts-based CRO under the Labcorp umbrella will give the testing giant a stronger foothold specifically in the Boston area, a hotbed for biotech and pharma development.

read more

Personalized T cells could offer an immunotherapy option to children with brain tumors

Scientists at Children’s National Hospital identified peptides that are unique to medulloblastoma tumors and then engineered T cells so they could recognize and target those proteins. They believe the therapy could offer a personalized immuno-oncology option for children diagnosed with this common tumor type.

read more

Healthcare associations, experts urge employers to swiftly adopt OSHA's 'commonsense' vaccination requirements

The American Medical Association, the American College of Physicians and dozens of other healthcare organizations and individual health experts called on employers to voluntarily implement OSHA's "reasonable and essential" vaccination requirements.

read more

Fierce Pharma Asia—Biocon, Viatris' insulin biosim launch; AstraZeneca China's deceleration; Huahai's FDA warning lift

Viatris launches two versions of its Biocon-partnered Lantus biosimilar. Growth of AstraZeneca's star China unit dropped. The FDA has lifted a warning lettering on the Chinese drug manufacturer behind a global valsartan recall three years ago. And more.

read more

Chutes & Ladders—Califf nominated to lead FDA again after Woodcock's lengthy interim stint

Robert Califf is President Joe Biden's nomination to lead the FDA, a post he held for the last year of Barack Obama's administration, after Janet Woodcock helmed the agency on a lengthy interim basis. Biogen's R&D chief Al Sandrock is retiring as the company reels from multiple hurdles to its Aduhelm rollout. And Pfizer's CFO becomes the latest executive at the Big Pharma to retire.

read more

Resources

Research: How Buffer Prep Services Alleviate Sudden Spikes in Campaign Volume

Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific

Whitepaper: Medable was able to cut costs in multiple clinical trials by over US$25,000,000

Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper.

Webinar: Using Next Best to Elevate your Omnichannel Marketing Strategy

Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: How the Chronic Insomnia Market Raises Big Questions About Digital Therapeutics

Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area.

Whitepaper: A Checklist for eCOA Solution Deployment

Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper.

2021 Report: Clinical Trial Management in a Post-Pandemic World

New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events